Abstract:Importance: Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021, the annual age-adjusted mortality of cirrhosis increased from 14.9 per 100 000 to 21.9 per 100 000 people. Observations: The most common causes of cirrhosis in the US, which can overlap, include alcohol use disorder (approximately 45% of all cases of cirrhosis), nonalcoholic fatty liver disease (26%), and hepatitis C (41%). Patients with cirrhosis experience symptoms including muscle cramps (approximately 64% prevalence), pruritus (39%), poor-quality sleep (63%), and sexual dysfunction (53%). Cirrhosis can be diagnosed by liver biopsy but may also be diagnosed noninvasively. Elastography, a noninvasive assessment of liver stiffness measured in kilopascals, can typically confirm cirrhosis at levels of 15 kPa or greater. Approximately 40% of people with cirrhosis are diagnosed when they present with complications such as hepatic encephalopathy or ascites. The median survival time following onset of hepatic encephalopathy and ascites is 0.92 and 1.1 years, respectively. Among people with ascites, the annual incidence of spontaneous bacterial peritonitis is 11% and of hepatorenal syndrome is 8%; the latter is associated with a median survival of less than 2 weeks. Approximately 1% to 4% of patients with cirrhosis develop hepatocellular carcinoma each year, which is associated with a 5-year survival of approximately 20%. In a 3-year randomized clinical trial of 201 patients with portal hypertension, nonselective β-blockers (carvedilol or propranolol) reduced the risk of decompensation or death compared with placebo (16% vs 27%). Compared with sequential initiation, combination aldosterone antagonist and loop diuretics were more likely to resolve ascites (76% vs 56%) with lower rates of hyperkalemia (4% vs 18%). In meta-analyses of randomized trials, lactulose was associated with reduced mortality relative to placebo (8.5% vs 14%) in randomized trials involving 705 patients and reduced risk of recurrent overt hepatic encephalopathy (25.5% vs 46.8%) in randomized trials involving 1415 patients. In a randomized clinical trial of 300 patients, terlipressin improved the rate of reversal of hepatorenal syndrome from 39% to 18%. Trials addressing symptoms of cirrhosis have demonstrated efficacy for hydroxyzine in improving sleep dysfunction, pickle brine and taurine for reducing muscle cramps, and tadalafil for improving sexual dysfunction in men. Conclusions and relevance: Approximately 2.2 million US adults have cirrhosis. Many symptoms, such as muscle cramps, poor-quality sleep, pruritus, and sexual dysfunction, are common and treatable. First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome.

Treatment of Pain in Cirrhosis: Advice to Caregivers of Those with Rock Livers

Navigating the 'Pits and Perils' of Analgesic Therapy in Advanced Liver Disease and Cirrhosis

The burden of significant pain in the cirrhosis population: Risk factors, analgesic use, and impact on health care utilization and clinical outcomes

Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review

Current and future pharmacological therapies for managing cirrhosis and its complications

Non-pharmacological Interventions for Muscle Cramps and Pain in Patients With Cirrhosis: A Systematic Review

Selection and rational use of analgesics in perioperative period of liver transplantation

Prescription rates of common medications in patients with decompensated cirrhosis in Germany

Key Insights and Clinical Pearls in the Identification and Management of Cirrhosis and Its Complications

Opioid use and risks in liver transplant candidates and recipients

Diagnosis and Management of Cirrhosis and Its Complications: A Review

Case Analysis of Cancer Pain Treatment for One Elder Patient with Colon Cancer Associated with Abnormal Liver Function

Drug treatments to prevent first decompensation in cirrhosis

Interpretation of Portal Hypertensive Bleeding in Cirrhosis:Risk Stratification, Diagnosis and Management:2016 Practice Guidance by the American Association for the Study of Liver Diseases

[CME: Outpatient Management of Patients with Liver Cirrhosis]

Improving Quality of Care in Patients with Liver Cirrhosis

Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists

Understanding the Complexities of Cirrhosis

Management of Alcoholic Cirrhosis of the Liver

Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis

Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine